| Quantity: | |
|---|---|
Multiple susceptible strains —C57BL/6, DBA/1 mice and Wistar rats—can meet different genetic backgrounds and experimental needs.
Clinical Relevance - Overview of human RA: autoimmune polyarthritis, synovial hyperplasia, pannus formation, cartilage erosion, and bone destruction.
Composite endpoint —body weight, clinical arthritis score, foot swelling, serum inflammatory markers (CRP, IL-6), joint histopathology (HE score).
Translational Value – Ideal for testing DMARDs (methotrexate, sulfasalazine), biologics (anti-TNF, anti-IL-6R), JAK inhibitors and novel immunomodulators.
IND Ready Packet – Research can be conducted in accordance with GLP principles.
Collagen-induced DBA/1 arthritis model
Collagen-induced C57BL/6 arthritis model
Collagen-induced Wistar arthritis model
• Efficacy testing of DMARDs (methotrexate, sulfasalazine, leflunomide, hydroxychloroquine)
• Evaluation of biologics (anti-TNF, anti-IL-6R, anti-IL-17, anti-CD20) and JAK inhibitors (tofacitinib, baricitinib)
• Target validation for autoimmune arthritis pathways (Th17, TNF, IL-6, RANKL)
• Biomarker discovery (anti-collagen antibodies, inflammatory mediators, acute phase proteins)
• Pharmacology and toxicology studies to support IND
scope | C57BL/6 CIA model | DBA/1 CIA model | Wistar rat CIA model |
Species/Strain | C57BL/6 mouse | DBA/1 mouse | vistar rat |
induction method | Immunization (day 0) and IFA booster (day 21) with type II collagen (CII) emulsified in CFA | ||
study time | 5-8 weeks | ||
critical endpoint | Body weight, clinical score, IL-6, joint histopathology (HE) | Body weight, clinical score, CRP, foot swelling, joint histopathology | Body weight, clinical score, foot swelling, joint histopathology, larger joints for imaging |
packet | Raw data, analysis report, clinical score, histological sections, serum analysis (IL-6, CRP), optional: anti-CII antibody, micro-CT imaging | ||
Q: What are the differences between CIA models of different strains?
Answer: DBA/1 mice are the most susceptible strain, with high incidence and severe arthritis. C57BL/6 mice develop moderate arthritis with a more variable onset that could be used for genetic modification. Wistar rats offer greater joint size for histopathology and imaging and are preferred for certain pharmacokinetic studies.
Q: Which model is best for testing biologics?
A: All three models are suitable. DBA/1 mice have been traditionally used for anti-TNF and anti-IL-6R studies due to high disease penetrance. C57BL/6 mice allow the use of knockout/transgenic strains. Rats offer advantages for continuous blood sampling and imaging.
Q: Can these models be used for IND support studies?
Answer: Yes. Studies can be conducted according to GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different collagen doses, boost times, combination therapies)?
Answer: Of course. Our scientific team tailors immunization regimens, treatment plans and endpoint analyzes to your specific drug candidate.
